Let the bidding war begin: Teva makes unsolicited offer for NuPathe

NuPathe Inc. has suddenly become the target of a bidding war. The Malvern, Pa., biopharmaceutical company disclosed Wednesday in a filing with the Securities & Exchnage Commission that it has received an unsolicited $114 million acquisition proposal from Teva Pharmaceuticals Industries...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.